

Clinical Pharmacy Program Guidelines for Biltricide

Program	Prior Authorization
Medication	Biltricide (praziquantel)
Markets in Scope	Arizona, California, Colorado, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Pennsylvania CHIP, Rhode Island, South Carolina
Issue Date	12/2013
Pharmacy and Therapeutics Approval Date	12/2020
Effective Date	2/2021

1. Background:

Biltricide is an anthelmintic indicated for the oral treatment of Schistosomiasis due to all species of schistosoma (for example, *Schistosoma mekongi*, *Schistosoma japonicum*, *Schistosoma mansoni* and *Schistosoma hematobium*), and Clonorchiasis and Opisthorchiasis due to liver flukes, *Clonorchis sinensis* and *Opisthorchis viverrini*.

2. Coverage Criteria:

<p>A. <u>Authorization</u></p> <p>1. Biltricide will be approved based on the following criteria:</p> <p style="padding-left: 40px;">a. The agent is being prescribed for one of the following:</p> <p style="padding-left: 80px;">(1) Infections due to schistosoma</p> <p style="text-align: center;">-OR-</p> <p style="padding-left: 80px;">(2) Infections due to the liver trematodes (flukes), <i>Clonorchis sinensis</i>/<i>Opisthorchis viverrini</i> (i.e., clonorchiasis or opisthorchiasis)</p> <p style="text-align: center;">Authorization will be issued for 12 months.</p>

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

Confidential and Proprietary, © 2021 UnitedHealthcare Services Inc.

- Supply limits may be in place.

4. References:

1. Biltricide [Package Insert]. Whippany, NJ: Bayer Pharmaceuticals; January 2019.
2. Centers for Disease Control. Parasites-Schistosomiasis: Resources for Health Professionals. October 28, 2020.
https://www.cdc.gov/parasites/schistosomiasis/health_professionals/index.html#tx
Accessed November 5, 2020.
3. Centers for Disease Control. Parasites-Clonorchis: Resources for Health Professionals. May 20, 2020. https://www.cdc.gov/parasites/clonorchis/health_professionals/index.html. Accessed November 5, 2020.
4. Centers for Disease Control. Parasites-Opisthorchis: Resources for Health Professionals. May 26, 2020.
https://www.cdc.gov/parasites/opisthorchis/health_professionals/index.html. Accessed November 5, 2020.

Program	Prior Authorization - Biltricide (praziquantel)
Change Control	
Date	Change
12/2013	New criteria
12/2015	Removed Albenza from entire guideline. Policy is renamed to “Biltricide”
10/2016	Annual review, updated policy template
7/2017	Annual review, updated background and policy template.
9/2017	Updated authorization duration to 12 months to allow for Dx to Rx implementation
10/2018	Removed age edit since there is not one coded. Updated references.
12/2019	Annual review, updated background and references.
12/2020	Annual review, updated references.